Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (7947)	11/3/2001 11:26:50 AM
From: Montana Wildhack	Respond to of 14101

Joe, You were absolutely right the last time you predicted a draw including how much and when. For anyone who doesn't know. Joe knows because he does the work of not only tracking all the trading; but analyzing the patterns with the events. This isn't insider information TSE. Just good solid work done by a clever individual from public information. I've seen enough over the months to know you will probably largely be right Joe. I looked at the last announcement of a placement and noticed it was bundled with another announcement. Let's hope the same is true this time. Wolf

To: Joe Krupa who wrote (7947)	11/5/2001 4:23:44 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Hi Joe, I do hope they draw this week as you predict. This will accomplish 2 things, 1. TK selling pressure will subside or disappear and 2. more cash in the bank. Takes away the bankruptcy fears, for the moment. Both of these contributed to the recent price splat. The draw will balance things out, hopefully leading to a rise in stock price. Unfortunately the draw will not help our stock price out due to the 1Q reporting. I was really bum-out from that. This is one area the company has some control over despite the revenue recognition rules, which even after scrutiney on this board, still doesn't add up. I thought DMX graduated from R&D status with the March launch in UK, to becoming a products company. Or better yet, a revenue generating company. That lead to my "disoriented ... reverted back ... Jr Placer Mining" comments last week. Most every products company I follow orchestrates their revenue generation as best they could. With the relentless hedging going on by TK, why was the company not more sensitive to stock valuation?? To me this was a glaring mistake by the company and it let down the shareholders in a big way. I have since listened to the AGM webcast twice. The first time, I encounted a steady stream of interuptions and also bum-out by DMX not booking 1Q revenues, I did not get an objective view of the AGM. I did find Rebecca very intelligent and professional in her response to questions but one. But at that time I felt Rebecca was also naive with some answers. However, after a second viewing, I had to take that back. How else could she have answered some of the tricker questions? For example, from my notes the Michael Beech (sp?) question about "Aqua financing initially seen as a gain in institutional ownership, to improve... merit but arbitrager instead of investor." Rebecca answered "it was structured as a private placement, Acqua has to disclose to the TSE every account they trade in and they need to following the terms of the Private Placement. TSE watch dog Neil Winchester (??) cited and can shut down Acqua. Rebecca has to rely on the TSE to monitor Acqua" I doubt the TSE has the resources nor time to monitor Acqua on behalf of little DMX, especially given the shear number of other companies listed on the TSE. But as a business person (and lawyer) Rebecca has to rely on the letter of the agreement and the law in her dealings. So not naive, what else can she do? What can anyone, in her shoes, do? I guess at one extreme, if Acqua breached the agreement and happened to be caught, then DMX definitely should sue. But I doubt this also. As she mentioned, delighted to have such financing in place especially in light of the current market conditions. At both viewings, I was shocked by the applause by some when asked for her resignation. "5)Not given enough information; not confid in management tjerefore suggestion to 1)call REK resignation 2) bod ..." I found her response to the second "shareholder" very well explained and clarified yet a second time. Why the applause? I doubt its the idea about management screwup brought forth by the second person at the mike, but rather 1) a perceived attack on all shareholders, ie by checking shareholder list which to me was brillant (attack not only that shareholder but all shareholders, ie the next person in line Mike Pulter (sp??) was somewhat defensive) and also more to do with share holder frustration with lack of meaningful ansers. Yes there are many questions and yes it does happen on some chat boards. Don't belittle the people on chat boards, they are in the end, shareholders (and shorters). It only helps the shorts and other adversaries. Its the little things, her thinking, her responses to the difficult situations and obsticles confronting the company that gives insight into the company and encourage greater confidence. These items are not secrets and they do not need to be held back. Rebecca should offer these tidbits more generously and openly, not only when drawn out of her when asked with questions that need to be worded very specifically. More communication of this type is greatly needed, even if it may be seen as idle chit chat. The dialogue that did take place was a great positive in my mind. An analogy using Rebecca's own comments regarding FDA and HC to drive home my point. The FDA is open, process well defined and there is dialog = Rebecca's confidence in the FDA process and eventual positive outcome. HC is closed and bitterly frustrating. As a shareholder, I want a more open DMX that offers dialogue and communications like the FDA analogy. I don't want a "HC like " closed ended company which DMX is preceived and happens to be, at least at this moment in time. Its very frustrating. DMX can change "if there is a will, there is a way." Another example where I got some insightful information, regarding her "recent meeting with Dundee fund president, claims that they still own all their shares, though in many account ... new venture equity funds." Another example, they "hired consultants, ex-FDA, and also McNeil has done a plant inspection and given their thumbs up." Whoa, good night!! See ya in the morning.

To: Joe Krupa who wrote (7947)	11/5/2001 6:08:04 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

Dimethaid draws $1.5 million against its financing facility - Company Continues Preparing for North American Launch of PENNSAID(R) - TORONTO, Nov. 5 /CNW/ - Dimethaid Research Inc. (TSE: DMX) announced today that the Company has effected a draw pursuant to its January 2001 private placement agreement with Acqua Wellington North American Equities Fund, Ltd. Dimethaid issued Acqua Wellington 415,512 shares of common stock and received net proceeds of $1,500,000. Proceeds are to be used largely to support the continued preparation for a North American launch of PENNSAID(R). "We are very pleased to have the flexibility in raising capital that our agreement with Acqua Wellington affords us, as we prepare to introduce PENNSAID(R) to osteoarthritis patients in Canada and the United States," said Rebecca Keeler, President and CEO. In the United States and Canada, more than US$8 billion is spent annually for oral non-steroidal anti-inflammatory drugs (NSAIDs), both selective and non-selective. Osteoarthritis affects 35 million people in these countries, and with the change in demographics expected as Baby Boomers enter their 50's and 60's in the coming years, the demand for the treatment of this disease is expected to continue to grow. Dimethaid Research Inc. is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic products that offer the potential to minimize the unwanted systemic effects of drug therapy on the body. Dimethaid's proprietary drug delivery technology utilizes the cell's tubule system to deliver drugs cell-to-cell. As a result, patients are able to treat localized conditions, such as osteoarthritis, while limiting the body's absorption of, and associated risks from, the medication. This technology has been applied first to produce PENNSAID(R) Topical Solution. The Company's business development strategy is to leverage its proprietary transdermal delivery technology into additional commercial products. For additional information on the Company, please visit www.dimethaid.com. This release may contain forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors outside management's control that could cause actual results to differ materially from those expressed in the forward-looking statements. A discussion of such risk factors is included in the Company's AIF filed with the OSC and includes, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, licenses and patents. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.